Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on September 30, 2015, covering events occurring on September 24, 2015, and September 30, 2015. The company is incorporated in Nevada and is based in Lexington, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Board of Directors: At the annual meeting on September 24, 2015, shareholders re-elected the entire board of directors: M. Scott Maguire, Firdaus Jal Dastoor, Roman Knyazev, Darlene Deptula-Hicks, and Dmitry Genkin.
- Capital Structure: On September 30, 2015, the company filed an Amendment to its Articles of Incorporation with the State of Nevada. This amendment was approved by shareholders at the September 24 meeting.
- Authorized Shares: The amendment increases the authorized Common Stock to 1,500,000,000 shares (par value $0.001) and authorizes 10,000,000 shares of Preferred Stock, which may be issued in one or more series.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document strictly reports on the election of directors and the amendment of corporate articles.
Key Facts for Investor Verification
- Verify the exact number of shares currently issued and outstanding versus the new 1.5 billion authorized limit.
- Confirm the terms and designation of any Preferred Stock series if issued in the future.
- Review the most recent Form 10-K for detailed biographical information on the re-elected directors.
- Check subsequent filings for any immediate issuance of stock under the new authorization.